Exact Mass: 793.6431342
Exact Mass Matches: 793.6431342
Found 498 metabolites which its exact mass value is equals to given mass value 793.6431342,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PC(20:3(5Z,8Z,11Z)/P-18:1(11Z))
C46H84NO7P (793.5985083999999)
PC(20:3(5Z,8Z,11Z)/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(5Z,8Z,11Z)/P-18:1(11Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(20:3(5Z,8Z,11Z)/P-18:1(9Z))
C46H84NO7P (793.5985083999999)
PC(20:3(5Z,8Z,11Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(5Z,8Z,11Z)/P-18:1(9Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(20:3(8Z,11Z,14Z)/P-18:1(11Z))
C46H84NO7P (793.5985083999999)
PC(20:3(8Z,11Z,14Z)/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(8Z,11Z,14Z)/P-18:1(11Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(20:3(8Z,11Z,14Z)/P-18:1(9Z))
C46H84NO7P (793.5985083999999)
PC(20:3(8Z,11Z,14Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(8Z,11Z,14Z)/P-18:1(9Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(20:3(8Z,11Z,14Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(8Z,11Z,14Z)/P-18:1(9Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(20:4(5Z,8Z,11Z,14Z)/P-18:0)
C46H84NO7P (793.5985083999999)
PC(20:4(5Z,8Z,11Z,14Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:4(5Z,8Z,11Z,14Z)/P-18:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(20:4(8Z,11Z,14Z,17Z)/P-18:0)
C46H84NO7P (793.5985083999999)
PC(20:4(8Z,11Z,14Z,17Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:4(8Z,11Z,14Z,17Z)/P-18:0), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(22:4(7Z,10Z,13Z,16Z)/P-16:0)
C46H84NO7P (793.5985083999999)
PC(22:4(7Z,10Z,13Z,16Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:4(7Z,10Z,13Z,16Z)/P-16:0), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The adrenic acid moiety is derived from animal fats, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-16:0/22:4(7Z,10Z,13Z,16Z))
C46H84NO7P (793.5985083999999)
PC(P-16:0/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-16:0/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:0/20:4(5Z,8Z,11Z,14Z))
C46H84NO7P (793.5985083999999)
PC(P-18:0/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:0/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:0/20:4(8Z,11Z,14Z,17Z))
C46H84NO7P (793.5985083999999)
PC(P-18:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(11Z)/20:3(5Z,8Z,11Z))
C46H84NO7P (793.5985083999999)
PC(P-18:1(11Z)/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(11Z)/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(11Z)/20:3(8Z,11Z,14Z))
C46H84NO7P (793.5985083999999)
PC(P-18:1(11Z)/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:1(9Z)/20:3(5Z,8Z,11Z))
C46H84NO7P (793.5985083999999)
PC(P-18:1(9Z)/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(9Z)/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(9Z)/20:3(8Z,11Z,14Z))
C46H84NO7P (793.5985083999999)
PC(P-18:1(9Z)/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(9Z)/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(9Z)/20:3(8Z,11Z,14Z))
C46H84NO7P (793.5985083999999)
PE(P-18:1(9Z)/20:3(8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(O-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))
C46H84NO7P (793.5985083999999)
PC(O-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(O-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of Oleyl alcohol at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. The Oleyl alcohol moiety is derived from beef fat, fish oil, while the eicosatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of Oleyl alcohol at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. The Oleyl alcohol moiety is derived from beef fat, fish oil, while the eicosatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
Alanine-betaxanthin
C46H84NO7P (793.5985083999999)
Phosphatidylcholine alkyl 16:0-22:5
C46H84NO7P (793.5985083999999)
Phosphatidylcholine alkenyl 18:0-20:4
C46H84NO7P (793.5985083999999)
PC(O-18:1/20:4)
C46H84NO7P (793.5985083999999)
PC(O-16:0/22:5)[U]
C46H84NO7P (793.5985083999999)
PC(O-16:0/22:6)
C46H84NO7P (793.5985083999999)
PC(O-18:0/20:5)
C46H84NO7P (793.5985083999999)
Lecithin
C46H84NO7P (793.5985083999999)
PE(38:4)
C46H84NO7P (793.5985083999999)
PC(P-20:0/18:4(6Z,9Z,12Z,15Z))
C46H84NO7P (793.5985083999999)
PC O-38:5
C46H84NO7P (793.5985083999999)
N-[(1S,2S,3R)-1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxy-7-phenyloctyl]hexacosanamide
2-[[(2S,3S,4R)-3,4-dihydroxy-2-(2-hydroxyhenicosanoylamino)-15-methylhexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[3-decoxy-2-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
2-[3-nonanoyloxy-2-[(17Z,20Z)-octacosa-17,20-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxy-3-tridecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-henicos-11-enoyl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-nonadec-9-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-hexadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-octadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-nonadecanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-heptadecanoyloxy-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-pentadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-tetracos-13-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-henicosanoyloxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-docos-13-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-icosanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-undecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-heptadec-9-enoyl]oxy-2-[(Z)-icos-11-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]octatriaconta-8,11,14,17,20,23,26,29,32,35-decaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]dotetraconta-9,12,15,18,21,24,27,30,33,36,39-undecaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]tetraconta-7,10,13,16,19,22,25,28,31,34,37-undecaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]tetratetraconta-8,11,14,17,20,23,26,29,32,35,38,41-dodecaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]tetraconta-10,13,16,19,22,25,28,31,34,37-decaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]dotetraconta-6,9,12,15,18,21,24,27,30,33,36,39-dodecaenamide
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]tricosa-4,8,12-triene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]henicosa-4,8,12-triene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]tetracosa-4,8,12-triene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]pentacosa-4,8,12-triene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E)-3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]pentacosa-4,8-diene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]henicosa-4,8-diene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]tricosa-4,8-diene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]docosa-4,8,12-triene-1-sulfonic acid
C47H87NO6S (793.6253761999999)
(4E,8E,12E)-2-(hexacosanoylamino)-3-hydroxydocosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxydocosa-4,8-diene-1-sulfonic acid
2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxydocosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoxy]propan-2-yl] (Z)-pentadec-9-enoate
C46H84NO7P (793.5985083999999)
3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]tetracosane-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(pentacosanoylamino)tricosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
C46H84NO7P (793.5985083999999)
(E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxydocos-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]propan-2-yl] tridecanoate
C46H84NO7P (793.5985083999999)
(4E,8E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxyhexacosa-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
C46H84NO7P (793.5985083999999)
(E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxyhexacos-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]propan-2-yl] pentadecanoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tricosoxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
C46H84NO7P (793.5985083999999)
2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyhexacosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] heptadecanoate
C46H84NO7P (793.5985083999999)
(E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]tetracos-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]tetracosa-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoate
C46H84NO7P (793.5985083999999)
(4E,8E,12E)-2-(docosanoylamino)-3-hydroxyhexacosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(tetracosanoylamino)tetracosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoxy]propan-2-yl] (Z)-tridec-9-enoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C46H84NO7P (793.5985083999999)
(4E,8E,12E)-3-hydroxy-2-(tricosanoylamino)pentacosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] (Z)-heptadec-9-enoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (10Z,13Z,16Z)-tetracosa-10,13,16-trienoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C46H84NO7P (793.5985083999999)
[3-icosoxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-dodecoxy-2-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-decanoyloxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(Z)-docos-13-enoxy]-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]oxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(Z)-docos-13-enoyl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-dodecanoyloxy-3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(Z)-icos-11-enoxy]-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
2-[4-[12-hydroxy-10,13-dimethyl-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]oxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
4-[2-[(Z)-tetracos-13-enoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-tetracosanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-henicos-11-enoyl]oxy-3-heptadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-docosanoyloxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-henicosanoyloxy-2-[(Z)-heptadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-nonadecanoyloxy-2-[(Z)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-dodecanoyloxy-2-[(Z)-hexacos-15-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-icos-11-enoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-pentadec-9-enoyl]oxy-3-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-icosanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-pentacosanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-docos-13-enoyl]oxy-3-hexadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] tricosanoate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] nonadecanoate
C46H84NO7P (793.5985083999999)
[2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-[(Z)-hexadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (Z)-henicos-11-enoate
C46H84NO7P (793.5985083999999)
[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-octadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-icosanoyloxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(Z)-icos-11-enoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-2-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
C46H84NO7P (793.5985083999999)
[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
C46H84NO7P (793.5985083999999)
[3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-2-[(Z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] henicosanoate
C46H84NO7P (793.5985083999999)
[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (Z)-nonadec-9-enoate
C46H84NO7P (793.5985083999999)
[2-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyl]oxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]tricos-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]pentacos-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8-dien-2-yl]tetracos-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctacosa-4,8-dien-2-yl]tridec-8-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]hexacos-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8-dien-2-yl]docos-11-enamide
(11Z,14Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-4-en-2-yl]hexacosa-11,14-dienamide
(18Z,21Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-4-en-2-yl]tetracosa-18,21-dienamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricosa-4,8-dien-2-yl]octadec-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]henicos-9-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonacosa-4,8-dien-2-yl]dodec-5-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]heptacos-12-enamide
(10Z,12Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricos-4-en-2-yl]octadeca-10,12-dienamide
(4Z,7Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacos-4-en-2-yl]hexadeca-4,7-dienamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacosa-4,8-dien-2-yl]hexadec-7-enamide
(14Z,16Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]docosa-14,16-dienamide
2-[2-hydroxy-3-[(27Z,30Z)-octatriaconta-27,30-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
4-[3-[(E)-pentacos-11-enoyl]oxy-2-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-henicos-9-enoyl]oxy-2-heptadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-dodec-5-enoyl]oxy-2-hexacosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-icosanoyloxy-3-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-docosanoyloxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-nonadecanoyloxy-3-[(E)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-2-[(7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoyl]oxy-3-[(E)-hexadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
4-[3-[(E)-docos-11-enoyl]oxy-2-hexadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]hexacos-17-enamide
[(2R)-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosa-4,8-dien-2-yl]icos-11-enamide
4-[3-pentadecanoyloxy-2-[(E)-tricos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8-dien-2-yl]docos-13-enamide
4-[3-icosanoyloxy-2-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-tetracosanoyloxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-henicosanoyloxy-2-[(E)-heptadec-7-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-2-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
4-[2-[(E)-tetracos-11-enoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-henicos-9-enoyl]oxy-3-heptadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-tetracosanoyloxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-dodecanoyloxy-2-[(E)-hexacos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-nonadecanoyloxy-2-[(E)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-docosanoyloxy-2-[(E)-hexadec-7-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-tetracos-11-enoyl]oxy-2-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-pentadecanoyloxy-3-[(E)-tricos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-dodecanoyloxy-3-[(E)-hexacos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-icos-11-enoyl]oxy-2-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-docos-11-enoyl]oxy-3-hexadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-pentacos-11-enoyl]oxy-3-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dodec-5-enoyl]oxy-3-hexacosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-icos-11-enoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-3-[(E)-icos-1-enoxy]-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
4-[3-pentacosanoyloxy-2-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-pentacosanoyloxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-pentadec-9-enoyl]oxy-3-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-pentadec-9-enoyl]oxy-2-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-henicosanoyloxy-3-[(E)-heptadec-7-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
[(2R)-3-[(E)-icos-1-enoxy]-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C46H84NO7P (793.5985083999999)
(E)-N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,6-dien-2-yl]hexacos-17-enamide
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8-dien-2-yl]tetracos-15-enamide
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]heptadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(18Z,21Z)-tetracosa-18,21-dienoyl]amino]heptadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(11Z,14Z)-hexacosa-11,14-dienoyl]amino]-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]henicosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxypentacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxynonadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(18Z,21Z,24Z,27Z)-triaconta-18,21,24,27-tetraenoyl]amino]undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxypentadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]heptadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]henicosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]henicosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]tricos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(20Z,23Z,26Z,29Z)-dotriaconta-20,23,26,29-tetraenoyl]amino]-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]tricosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxypentacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxypentacosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]amino]tridec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(15Z,18Z,21Z,24Z,27Z)-triaconta-15,18,21,24,27-pentaenoyl]amino]undecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]heptadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxynonadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(17Z,20Z,23Z,26Z,29Z)-dotriaconta-17,20,23,26,29-pentaenoyl]amino]-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]henicos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]amino]tridecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxynonadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxynonadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxypentacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxynonadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxytetracosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]docosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
1-[(1Z)-octadecenyl]-2-[(5Z,8Z,11Z,14Z)-icosatetraenoyl]-sn-glycero-3-phosphocholine
C46H84NO7P (793.5985083999999)
A phosphatidylcholine (P-38:4) in which the alkenyl group at position 1 is (1Z)-octadecenyl and the acyl group at position 2 is (5Z,8Z,11Z,14Z)-icosatetraenoyl.
1-[(9Z)-octadecenyl]-2-[(5Z,8Z,11Z,14Z)-eicosatetraenoyl]-sn-glycero-3-phosphocholine
C46H84NO7P (793.5985083999999)
A phosphatidylcholine O-38:5 in which the alkenyl group at position 1 is (9Z)-octadecenyl and the acyl group at position 2 is (5Z,8Z,11Z,14Z)-eicosatetraenoyl respectively.
phosphatidylcholine (O-18:1/20:4)
C46H84NO7P (793.5985083999999)
A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the acyl group contains 20 carbons and 4 double bonds while the alkyl group contains 18 carbons and 1 double bond.
phosphatidylcholine O-38:5
C46H84NO7P (793.5985083999999)
A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 38 carbons and 5 double bonds.
MePC(37:5)
C46H84NO7P (793.5985083999999)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(40:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(41:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(42:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved